Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada

被引：0
|
作者：
Jodi Cameron
Jennifer Forgie
Alicia Ring
Stephanie Santucci
Caroline Rizk
Hoang Pham
John O’Quinn
William H Yang
机构：
[1] Allergy and Asthma Research Centre,Department of Clinical Immunology and Allergy
[2] McGill University,undefined
[3] University of Ottawa Medical School,undefined
来源：
Allergy, Asthma & Clinical Immunology | / 10卷 / Suppl 2期
关键词：
Asthma; Health Care Utilization; Oral Corticosteroid; Allergic Asthma; Asthma Exacerbation;
D O I：
10.1186/1710-1492-10-S2-A5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Omalizumab Enrollment in a Tertiary Care Allergy and Asthma Clinic in Canada
    Hoang Pham
    Cameron, Jodi
    Forgie, Jennifer
    Ring, Alicia
    Diana Pham
    Santucci, Stephanie
    Rizk, Caroline
    O'Quinn, John W.
    Yang, William H.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB2 - AB2
  • [2] The Observed Incidence of Anaphylaxis in Patients Receiving Omalizumab in a Tertiary Allergy and Asthma Clinic in Canada
    MacRae, Megan
    Santucci, Stephanie
    Rizk, Caroline
    Karsh, Jacob
    Yang, William H.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB4 - AB4
  • [3] An Update On: The Observed Incidence of Anaphylaxis in Patients Receiving Omalizumab in a Tertiary Allergy and Asthma Clinic in Canada
    Valois, Jodi
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB15 - AB15
  • [4] The observed incidence of adverse reactions in patients receiving omalizumab therapy in a tertiary allergy and asthma clinic in Canada
    Harrison, R.
    Santucci, S.
    MacRae, M.
    Yang, W. H.
    [J]. ALLERGY, 2015, 70 : 350 - 351
  • [5] The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
    MacRae M.
    Santucci S.
    Karsh J.
    Yang W.H.
    [J]. Allergy, Asthma & Clinical Immunology, 10 (Suppl 2)
  • [6] Omalizumab (Xolair) for Food Allergy
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1699): : 54 - 56
  • [7] Omalizumab (xolair) for treatment of asthma
    Davydov, L
    [J]. AMERICAN FAMILY PHYSICIAN, 2005, 71 (02) : 341 - 342
  • [8] Omalizumab (Xolair):: An anti-IgE antibody for asthma
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1163): : 67 - 68
  • [9] Intubation secondary to asthma exacerbation in a patient with asthma receiving Xolair (Omalizumab)
    Jacobs, Zachary D.
    Guajardo, Jesus R.
    [J]. PEDIATRIC PULMONOLOGY, 2008, 43 (01) : 102 - 103
  • [10] Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt
    Thompson, Philip J.
    Misso, Neil L.
    Woods, John
    [J]. RESPIROLOGY, 2007, 12 : S29 - S34
12345